You are here: Industry Insights > Rheumatoid Arthritis

News List

Common Treatments for Rheumatoid Arthritis David Orchard-Webb
July 01, 2024
Rheumatoid arthritis (RA) is a chronic inflammatory disorder that primarily affects joints but can also impact other systems in the body, including the skin, eyes, lungs, heart, and blood vessels.
Second Biosimilar Tocilizumab Injection approved for marketing www.nmpa.com
January 18, 2023
Second Biosimilar Tocilizumab Injection approved for marketing.
Theramex, Enzene Biosciences Partner on Arthritis Treatment contractpharma
January 05, 2022
Will develop and commercialize Tocilizumab, a biosimilar for the treatment of rheumatoid arthritis.
Rheumatoid Arthritis accounts for 18.9% share of global Immunology clinical trial activity in 2020 pharmaceutical-technology
June 17, 2021
Rheumatoid Arthritis accounted for an 18.9% share of the global clinical trials within the Immunology therapy area in 2020, registering a decrease of 4.4% when compared with the last ten-year average of 23.3% share, according to GlobalData.
NICE broadens access to treatments for rheumatoid arthritis pharmatimes
June 16, 2021
The National Institute for Health and Care Excellence (NICE) has published final draft guidance broadening access to several treatment for patients with moderate to severe rheumatoid arthritis.
Biogen Welcomes NICE Announcement on TA375 as a Landmark Decision for UK Patients with Moderate Rheumatoid Arthritis firstwordpharma
June 11, 2021
Biogen UK welcomes the decision by the National Institute for Health and Care Excellence (NICE) to broaden patient access to biologics, including biosimilars, to treat moderate rheumatoid arthritis (RA).
NICE publishes final guidance backing Jyseleca for rheumatoid arthritis pharmatimes
January 22, 2021
The National Institute for Health and Care Excellence (NICE) has published its final appraisal determination (FAD) recommending the use of Gilead Sciences and Galapagos’ Jyseleca (filgotinib) for the treatment of rheumatoid arthritis (RA).
Henlius Adalimumab Biosimilar Approved by NMPA prnasia
December 09, 2020
Shanghai Henlius Biotech, Inc. announced that the adalimumab biosimilar HLX03, developed and manufactured by the Company independently, has been approved by the National Medical Products Administration (NMPA) for the treatment of rheumatoid arthritis ...
SynAct Pharma Announces Positive Interim Phase 2 Data of AP1189 in Rheumatoid Arthritis prnasia
November 09, 2020
SynAct Pharma AB, a clinical stage biopharmaceutical company developing novel therapies of inflammatory diseases, today announced that an independent Data Safety Monitoring Board (DSMB) has reviewed unblinded and validated data from part 1 of the ...
NICE backs AbbVie’s Rinvoq for severe active rheumatoid arthritis pharmatimes
November 09, 2020
The UK’s National Institute for Health and Care Excellence (NICE) has recommended AbbVie’s Rinvoq (upadacitinib) for people with previously treated severe active rheumatoid arthritis (RA).

Previous page 1 2 3 4 5 6 Next page